Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard — TradingView News
On July 20, 2026, the company received notice from Nasdaq that it failed to maintain the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until January 19, 2027, to regain compliance, with potential for an additional 180 days if conditions are met. Trading continues on the Nasdaq Capital Market under the symbol ONCY.
Original SEC Filing: ONCOLYTICS BIOTECH INC [ ONCY ] – 8-K – Jul. 24, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.